Moderna
MRNAMarket price data through July 31, 2026.
Performance
Aug 2021 – Jul 2026
Track record
How this pick has done since Benson first called it.
- Benson Return
- +1%
- How much this stock is up since Benson first picked it — measured from the price at the time of that first pick, not from today.
- First pick price
- ~$54
- Roughly what one share cost when Benson first picked this stock. This is the starting line for the Benson Return.
- Tracking since
- April 2026
- The month this stock first became a Benson pick.
- Tracking duration
- 3 months
- How long Benson has been tracking this pick.
About Moderna
Moderna is the biotech company that became a household name with its COVID vaccine. It uses mRNA, a set of instructions that teaches your body to build a protein and defend itself. The COVID windfall is long gone, and Moderna is now trying to prove it can win with flu shots, RSV shots, and cancer treatments instead.
The case for and against
Both sides of the story, in plain English.
- Fifth Product
Moderna is on the verge of adding a fifth approved product, with a U.S. decision on its seasonal flu vaccine due August 5th after an advisory panel backed it unanimously. It also signed a European contract covering up to 24 million doses of its RSV shot and won new approvals in Australia, Mexico, Japan, and Taiwan. That is why the company still expects sales to grow up to 10% this year.
- Leaner Machine
Moderna keeps squeezing costs. Research spending fell 7% to 651 million dollars last quarter and overhead fell 6% to 216 million dollars. Because of that, the company now expects to finish the year with 4.7 to 5.2 billion dollars in the bank, about 200 million dollars better than it previously planned.
- Cash Clock
Moderna lost 782 million dollars in a single quarter. Its cash pile dropped from 7.5 billion to 6.9 billion dollars in three months, and it paid another 950 million dollars in July to settle a lawsuit. Every quarter without a hit product shortens the runway.
- Pipeline Misses
The norovirus vaccine, aimed at the stomach bug that shuts down cruise ships, failed to clear the bar at an early look at its big trial, and now needs more patients enrolled. Meanwhile quarterly sales were just 145 million dollars, versus 142 million a year ago, so almost everything rides on the pipeline.
Other companies we track
How to read this page
This automated research summary uses Financial Modeling Prep market data through 2026-07-31. Model signals, scores, and risk labels can change and may be incomplete or wrong.
Want Benson to watch MRNA for you?
Get the app to follow every Benson pick live — and let Benson do the research for you.
Download on the App Store
Download Android app